Skip to main content
OpenTrials
Completed

NCT Number: NCT05910008

O-ARM Stereotactic Imaging in Deep Brain Stimulation for Parkinson's Disease

During deep brain stimulation procedures in Parkinson's disease (PD), the most important prognostic element is the positioning of the surgical electrode in the subthalamic nucleus which is the anatomical target. The main objective of this project is therefore to compare 2 techniques thanks to a prospective comparative randomised open-label study: the use of O-ARM to acquire stereotactic imaging directly in the operating room and the standard technique requiring stereotactic imaging to be performed in the radiology department.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Toulouse

Toulouse, 31000, France

About this study

Prior to electrode implantation we perform stereotactic imaging which requires the fixation of a stereotactic frame on the patient's head before imaging (Magnetic Resonance Imaging MRI / Computed Tomography CT). Currently, it is necessary to transfer the patient to the imaging department outside of the operating room after the stereotactic frame has been placed, for imaging (either MRI or CT) and then to return to the operating room to begin the electrode implantation procedure. Since 2016, the new generation O-Arm 2 allows the acquisition of stereotactic imaging with the stereotactic frame in place by increasing the field of view (40 cm versus 20 cm previously) directly in the operating room. As a result, the transfer step to the MRI and CT scanner preoperatively may no longer be necessary, and the procedure can be started more quickly with greater comfort and safety for the patient and the anaesthesia team. Several teams around the world have begun to use framed O-Arm as the gold standard for stereotactic imaging. However, no randomised controlled study has been performed to date comparing O-Arm stereotactic imaging with pre-operative CT and/or MRI reference imaging.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a diagnosis of idiopathic Parkinson's disease at the stage of motor fluctuations despite optimal medical treatment
  • Indication for Deep Brain Stimulation (DBS) of the subthalamic nucleus approved by the local multidisciplinary deep brain stimulation committee after an operability assessment (see Appendix)
  • Informed and signed patient consent
  • Affiliation to a social security scheme

Exclusion criteria

  • Significant cognitive decline assessed in a dedicated multidisciplinary consultation
  • Contraindication to Magnetic Resonance Imaging (MRI)
  • Presence of pathologies contraindicating deep brain stimulation
  • No contraceptive treatment for women of childbearing age
  • Pregnant or breastfeeding woman
  • Anticoagulant or antiaggregant treatment that cannot be stopped
  • Persons under legal protection (persons deprived of liberty or incapable of giving consent or under guardianship or tutelage...)
  • Patient with severe psychiatric disorders

Treatment and study plan

O-Arm Stereotactic imaging

Procedure

Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)

Standard Stereotactic imaging

Procedure

Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)

Primary outcomes

  1. The absolute accuracy of Deep Brain Stimulation electrode implantation

    Time frame: 48 hours

    The radial distance between the theoretical target and the electrode in the plane of the target regardless of the chosen trajectory (central, anterior, lateral). This distance corresponds to the minimum error between the target and the electrode. This measurement is made from the postoperative brain scan.

Secondary outcomes

  1. The anatomical accuracy of Deep Brain Stimulation electrode implantation

    Time frame: 48 hours

    Automatic calculation of the vector distance between the middle of pad 1 on the electrode and the theoretical target by software.

  2. Central and alternate position of the electrodes rate

    Time frame: 1 day

    Comparison of the anatomical location of the electrode compared to the anatomical target (subthalamic nucleus) after matching preoperative Magnetic Resonance Imaging (MRI) images

  3. Surgical Times

    Time frame: 1 day

    Time from the end of the stereotactic frame to the surgical incision and time from the entry into room to the exit from room after generator implantation.

  4. Clinical effectiveness

    Time frame: 6 months

    Comparison of The Unified Parkinson's Disease Rating Scale (UPDRS) II, III and IV scores between baseline and 6 months and then at 6 months between the 2 groups.

    The UPDRS scale is composed of 47 items grouped into three parts : II, III and IV. Responses scale ranging from 0 (normal/no symptoms) to 4 (severe).

  5. Daily dose of Levodopa decrease

    Time frame: 6 months

    The change in Levodopa Equivalent Daily Dose (LEDD) before surgery and at 6 months compared between the 2 groups. This LEDD corresponds to the amount of antiparkinsonian treatments prescribed to the patient

  6. Adverse effect rate

    Time frame: 6 months

    Clinical reporting of patient events/adverse reactions

  7. Correlation between absolute accuracy and clinical effectiveness

    Time frame: 6 months

    Correlation between radial accuracy and UPDRS score for both groups

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Official study title

Evaluation of Intraoperative O-ARM Stereotactic Imaging Versus Conventional Pre-operative Stereotactic Imaging in Deep Brain Stimulation for Parkinson's Disease

Acronym: STEREOBLOC

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jun 18, 2023
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.